VAN NUYS, CA / ACCESSWIRE / July 30, 2019 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today the results from four years of its Extensive Parts Remanufacturing (EPR) program, implemented back in 2015, to reduce material costs associated with the company’s expanding aftermarket service business. The cumulative results have generated $15 million in cumulative savings since inception, demonstrating the continued sustainable progress against its strategic initiative to increase gross margin and achieve its near-term profitability goals.

“The recent success of our parts remanufacturing program has been masked by a temporary vendor part reliability issue and the overall availability of used 40,000-hour parts to build up a significant pool of parts available to be remanufactured. However, as we enter the back half of this fiscal year both these issues should be behind us, and investors should begin to see the true gross margin impact of our EPR program,” said Darren Jamison, Capstone’s President and Chief Executive Officer.

The company previously announced its focus on improving the clean and green microturbine business in areas that it has direct control of, and in areas that are not impacted by outside market forces, macroeconomic conditions, geopolitical events, tariffs or trade wars.

The current management focus is on the following areas to improve the business:

Reducing costs through the Extensive Parts Remanufacturing (EPR) program
Reducing material costs through the new Capstone Strategic Supplier (CSS) program
Developing a new 10 MW Capstone Long-Term Rental program
Expanding Factory Protection Plan (FPP) service contract attachment rates
Developing and expanding the new Distributor Support System (DSS) program
Increasing overall aftermarket spare parts revenue and gross margin

The EPR program was launched as a lean manufacturing and continuous improvement project, and since its inception in 2015, Capstone’s remanufacturing efforts have contributed to a cost avoidance of over $15 million in service parts and warranty and FPP spend, with savings and gross margin increasing year-over-year. The EPR focuses on the strategic reusing, repurposing, and refurbishing of microturbine parts returning from the approximately 9,000 microturbines worldwide from both scheduled and unscheduled maintenance activities.

Kirk Petty, Capstone’s Senior Vice President of Manufacturing, noted that “at the start of the project, a collaborative team of engineering, quality, customer service, and manufacturing members participated in determining the most economically viable solutions for dispositioning returning product.” Mr. Petty continued, “While the initial focus of the project team concentrated on the basic cleaning, inspection and screening of parts, the overall remanufacturing program smartly evolved into developing cost-efficient rework methods. In some cases, these remanufacturing efforts resulted in savings of over 90% of the cost of a new part, while achieving the same original standard of quality our customers have come to expect.”

The EPR program also helps to address a Capstone corporate value initiative, which is to reduce its global environmental footprint both in its products and in its microturbine manufacturing efforts. “Our remanufacturing program helps reduce, reuse or recycle the overall amount of material that would have normally gone into landfills or other waste streams, in keeping with our ISO 14001 environmental objectives, and our social and corporate responsibility,” said Mr. Jamison. “This is essentially an environmentally friendly steel recycling program that is on top of the estimated $253 million in annual energy costs and 350,000 tons of carbon we have saved end-use customers,” added Mr. Jamison.

The remanufacturing program coincides with multiple efficiency improvements the company has realized over the last several years in its critical aftermarket business, supporting its stated strategic goal to completely absorb all operating expenses through margins contributed from the aftermarket business. “In realizing the initial successes of the remanufacturing program at Capstone’s headquarters, we determined that even greater savings could occur by moving the processes upstream to our forward-operating United Kingdom facility,” stated Jeff Foster, Capstone’s Senior Vice President of Customer Service and Product Development.

“Over the last several years, our Capstone United Kingdom facility has been transformed from a field services hub to a state-of-the-art facility that has similar remanufacturing capabilities to that of our corporate worldwide manufacturing headquarters in California. When we complete this U.K. transformation project in 2020, we will have greatly reduced the costs associated with our growing fleet operating in Europe, Russia, the Middle East, and Africa. We believe the expected results from the remanufacturing program will be reflected in future continued, sustainable improvements in aftermarket gross margins, as well as overall company margins,” concluded Mr. Foster.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq: CPST) is the world’s leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, providing scalable systems focusing on 30 kWs to 10 MWs that operate on a variety of gaseous or liquid fuels and are the ideal solution for today’s distributed power generation needs. To date, Capstone has shipped over 9,000 units to 73 countries and has saved customers an estimated $253 million in annual energy costs and 350,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn and YouTube.

Forward-Looking Statements

This press release contains “forward-looking statements,” as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as “expects,” “believes,” “objective,” “intend,” “targeted,” “plan” and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone’s filings with the Securities and Exchange Commission that may cause Capstone’s actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

“Capstone” and “Capstone Microturbine” are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 553941

Initial Multi-Month Pilot Program

LAS VEGAS, NV / ACCESSWIRE / July 30, 2019 / Beyond Commerce, Inc. (OTCQB:BYOC) (the “Company”), a provider of B2B internet marketing analytics, technologies and services, announced today the signing of Thermo Fisher Scientific into an initial multi-month pilot program with Service 800.

Service 800 will design programs and provide resources to measure every day customer service. The program methodology goal is to deliver accurate metrics needed to build and measure an effective customer journey map.

Geordan Pursglove, Beyond Commerce’s Chief Executive Officer, commented, “We are very excited to work with an industry leader like Thermo Fisher and look forward to completing a successful pilot program to transition into a long-term business relationship. We believe our Service 800 program reveals the actions and behaviors that accomplish long-term objectives for companies such as Thermo Fisher Scientific. We look forward to working with Thermo Fisher Scientific in assisting with their customer service data analytics.”

About Thermo Fisher

Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For additional information, please visit: https://www.thermofisher.com/us/en/home.html

About Beyond Commerce, Inc.

Beyond Commerce, Inc. (OTCQB: BYOC) is focused on business combinations of “big data” companies in global B2B internet marketing analytics, technologies and services. The Company’s objective is to develop and deploy disruptive strategic software technology that will build on organic growth potential and to exploit cross-selling opportunities. Beyond Commerce plans to offer a cohesive global digital product and services platform to provide clients with a single point of contact for their big data, marketing and related sales initiatives. For additional information, please visit: https://beyondcommerceinc.com and https://www.service800.com.

Twitter: @incbyoc
Facebook: fb.me/incbyoc

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the “safe harbor” created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “design,” “estimate,” “except,” “forecast,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negatives or other tense of such terms and other similar expressions intended to identify forward-looking statements and similar expressions. We use forward-looking statements relate to future events or future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.

Contact Information:

investors@beyondcommerceinc.com
IR@StratconAdvisory.com
p702-675-8022

SOURCE: Beyond Commerce, Inc.

ReleaseID: 553936

July 31 Event with Reseller Partner MNG Rides

TOCCOA, GA / ACCESSWIRE / July 30, 2019 / Galaxy Next Generation, Inc. (OTCQB:GAXY) (“Galaxy” or the “Company), a provider of interactive learning technology solutions, today announced its participation at the upcoming Robins AFB Tech Expo in Warner-Robins, Georgia on Wednesday, July 31.

For more information on the Robins AFB Tech Expo, please visit: https://fdaexpo.com/event.php?id=270#.XT9ZcC2ZOCc

Gary LeCroy, Galaxy’s Chief Executive Officer, commented, “We are excited to be attending the tradeshow with our new reseller partner, MNG Rides, who has a heavy focus into the military, a new and untapped vertical for us. MNG Rides has added our products to their purchasing contracts for the military bases and this is the first show we are doing together to showcase the G2 product line.”

About Robins AFB Tech Expo

This is the major technology event for Robins AFB each year. The Annual Expo attracts 250+ personnel and this is the ONLY Technology Expo held directly on Robins AFB. Robins Air Force Base is the state’s largest industrial complex employing over 24,000 workers including civilians, active duty and contractors, performing a wide range of logistics activities. Warner Robins Air Logistics Center has command jurisdiction over Robins Air Force Base and is host to over 40 separate hosted organizations. The Warner Robins Air Logistics Center, one of three major air logistics centers in the Air Force Materiel Command, supports the goals and objectives of the AFMC and other related Air Force/DOD activities by providing affordable combat superiority, readiness, and sustainability to the war fighters. WR-ALC provides worldwide logistics management, engineering, and organic depot maintenance for various aircraft. WR-ALC has worldwide management and logistics support responsibility for all Air Force helicopters, special operations aircraft, missiles, vehicles, and general purpose computers. Robins manages more than 200,000 items that represent the full range of avionics functions and technology. The center is part of the Air Force Materiel Command headquartered at Wright-Patterson Air Force Base, Ohio.

About Galaxy Next Generation, Inc.

Galaxy Next Generation (OTCQB: GAXY) is a provider of interactive learning technology solutions that allows the presenter and participant to engage in a fully collaborative instructional environment. Galaxy’s products include Galaxy’s own private-label interactive touch screen panel as well as numerous other national and international branded peripheral and communication devices. Galaxy’s distribution channel consists of 22+ resellers across the U.S. who primarily sell the Company’s products within the commercial and educational market. Galaxy does not control where resellers focus their resell efforts, although generally, the K-12 education market is the largest customer base for Galaxy products – comprising nearly 90% of Galaxy’s sales.

For additional information, please visit our website at: www.galaxynext.us

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investors Contact:

mgilbert@magellanfin.com
p317-361-2392

SOURCE: Galaxy Next Generation, Inc.

ReleaseID: 553935

PHOENIX, AZ / ACCESSWIRE / July 30, 2019 / The Stock Day Podcast welcomed BioCorRx (OTCQB:BICX) (“the Company”), an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. COO and CFO, Lourdes Felix, joined Stock Day host Everett Jolly.

Jolly began the interview by asking Felix why investors should take a look at the Company and its current projects. Felix explained that the Company is a healthcare company focused on developing treatment solutions for substance abuse and related disorders. Their flagship program is the BioCorRx Recovery Program, which is a medication-assisted treatment (MAT) solution for substance use disorders. With a B2B strategy, the Company’s customers are treatment facilities and medical providers that offer the program to their patients.

Felix also shared that the Company’s subsidiary, BioCorRx Pharmaceuticals, Inc., has its own pipeline of products including different deliveries for the drug, naltrexone. The Company recently received nearly $5.7 million from NIDA to help develop BICX102, a sustained release pellet of naltrexone for which the Company is seeking FDA approval.

Jolly then asked what makes the Company’s treatment program unique. Felix shared that their treatment program stands apart from others on the market as it combines the medication along with the psycho-social support. “The combination of the medication with the psycho-social support is very important and crucial to long-term recovery for these individuals.”, stated Felix. “We’re not just providing the medication, we’re providing a comprehensive program.”, she added.

Jolly asked about the Company’s recent announcement of their UnCraveRx program. Felix explained that this weight loss program is expected to be fully available in October and helps patients manage cravings through medication. This program also offers a virtual application, which is available now. Through the app, patients can take advantage of a variety of tools and resources to guide them through their weight loss journey. “For any support that is needed, there is always someone readily available on the other end.”, stated Felix.

Jolly then noted that the Company was able to raise a substantial amount of funds in April of this year and asked about the use of those funds. Felix shared that the funds are currently being utilized to launch the UnCraveRx program, as well as for the Company’s plan to uplist. “Our plan for uplisting is still a go, and we’re still working on meeting the requirements. We’re well on our way to getting there. We’re excited.”, shared Felix.

To close the interview, Felix explained that the Company has a truly diverse selection of programs and products, and is only continuing to grow.

To hear Lourdes Felix’s entire interview, follow the link to the podcast here:

https://audioboom.com/posts/7328508-biocorrx-joins-the-stock-day-podcast-to-discuss-their-growing-treatment-and-weight-loss-programs

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About BioCorRx

BioCorRx Inc. (BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit www.beataddiction.com for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication-assisted program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com.

BioCorRx Inc.

investors@BioCorRx.com
714-462-4880

Investor Relations:

Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE CONTACT:

Stock Day Podcast
602-441-3474

SOURCE: Stock Day Media

ReleaseID: 553909

Key Management appointments, including Raymond W. Urbanski MD, PhD, former business unit Chief Medical Officer at Pfizer Inc., as Chief Executive Officer provides extensive industry leading expertise, strategic focus and discipline on the execution of corporate initiatives

Purposefully built strategic business units focused on leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing markets

Multiple expected near-term value driving milestones

BEVERLY HILLS, CA / ACCESSWIRE / July 30, 2019 / Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), a vertically integrated company focused on the development of science-driven cannabinoid biopharmaceuticals and the production of high-quality CBD products, today provided a corporate update and business outlook for the remainder of 2019.

Corporate Highlights

Renewed strategy focused on leveraging endocannabinoid system to develop high-value products across three separate business units, including:Biopharmaceuticals: goal to develop novel therapeutics to treat serious diseases across a range of therapeutic areas, including metabolic, peripheral neuropathy and progressive lung disease CBD Products: multiple brands offering high-quality CBD products to the highest regulatory standards;Bolstered leadership team with highly qualified individuals including Raymond W. Urbanski MD, PhD, as Chief Executive Officer, former business unit Chief Medical Officer at Pfizer Inc. and well-established industry leading expert with over 20 years of experience in clinical development, research and pharmaceutical industry expertise across oncology, cardiology, endocrinology, and immunology;Appointed Martin Schroeder to the Scientific Advisory Board and as President of Applied BioPharma. Mr. Schroeder has over 30 years of experience in the pharmaceutical and biotech industries and has helped many biotech and pharmaceutical companies conduct search and evaluation of compounds and molecules;Launched multiple new products and expanded into the Beverage and Health / Wellness category with Remedi Spa and Remedi Beverage and Shot;Commenced discussions regarding proposed scientific trials with two leading Universities specializing in Veterinary Medicine;Announced the acquisition of Trace Analytics with over 65 years of combined experience in the global testing market for Cannabis and Hemp;Partnered with Boxing Heavyweight Champion, Shannon “The Cannon” Briggs to launch Champ Organics, an athlete-focused cannabidiol (“CBD”) based health and wellness supplements product line that enhances training and recovery; andLaunched robust business development initiative to build biopharmaceuticals pipeline.

“Over the course of my academic and pharmaceutical career, I have developed a keen interest in the benefits of cannabinoids and their ability to address a wide range of disease states. I saw a great deal of potential in Applied’s science-based approach to the endocannabinoid system, which ultimately drove me to join at what I believe is a pivotal time in the Company’s history. Now with the right team in place and a renewed focus on our corporate and clinical strategies, I believe we have the potential to drive value for all stakeholders and impact areas of significant unmet need in established and rapidly growing markets,” commented Dr. Raymond Urbanski, Chief Executive Officer. “As we look towards the rest of 2019, we remain focused on the critical importance of taking the necessary steps to build a solid foundation from which we can launch future expansion and growth. With all our strategic approaches in place, we believe we are well-positioned to unlock the full potential of Applied BioSciences.”

Applied BioPharma

The Applied BioPharma business unit is focused on the development and commercialization of novel therapeutics to treat serious diseases by leveraging industry leading pipeline of endocannabinoid system-targeted drug candidates.

The Company is actively seeking in-license opportunities with the goal of developing an industry leading pipeline of endocannabinoid system-targeted drug candidates that address significant unmet needs across a wide range of therapeutic areas. The Applied management team expects to announce at least one in-licensing agreement before year end.

Applied Products

The Applied Products business unit currently consists of eight different brands of hemp-derived, THC-free, pharmaceutical grade CBD isolates and distribution products, all of which ship to the majority of U.S., as well as to multiple non-US countries. The Company’s portfolio currently includes consumer, animal health, women’s health and sports medicine products.

Applied Products operates under a differentiated approach to quality and regulatory practices within the industry, which it believes well-positions them to be leaders in the market and access the significant opportunity for revenue generation. All CBD products utilize the most proven and effective production methods to ensure the highest quality output. The Company’s Full Spectrum products are made using CO2 Extraction, which allows for the proper retention of cannabinoids and terpenes vs a distillate, and a winterization process. Applied’s THC Free products are CBD Isolate infused. This isolation process leaves behind pure pharmaceutical grade CBD only, ensuring the highest quality is achieved. Additionally, the Company’s Nano CBD Isolate products use a specialized Nano-Particulizer, a process which creates a pure nano-molecule.

“The CBD industry continues to be of great interest among the medical and investment community. We have seen rapid growth and continue to witness advancements in the space, however current products on the market are not high quality or are not actually what the label claims them to be. Our team sees room for significant improvement and believe we have a competitive advantage by offering high-quality products through our differentiated approach,” said Scott Stevens, Founder and Chairman of the Board.

Trace Analytics, Inc.

Trace Analytics Inc., a majority owned subsidiary of Applied, is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology. The focus of the team is to ensure compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

The Company is actively establishing a global medical and consumer platform and multiple brands through creating a platform to partner and invest in various segments in the consumer industry and establish key exclusive strategic alliances which serve to accomplish the task of becoming the market leader. For more information, please visit: http://traceanalytics.com

Upcoming Milestones Expected to Drive Value

In-license product candidates to build robust pipeline for the Applied BioPharma division;Explore strategic options for non-dilutive funding with Trace Analytics;Successfully execute overall strategy of the Company and Business Development efforts;Engage with key stakeholders in the investment community and execute on the robust effort to raise awareness of the Company; andUplist to a National Exchange.

Dr. Urbanski concluded, “Our priority moving forward is to successfully execute our corporate strategy. We continue to make significant steps to raise the awareness of the Company with multiple stakeholders in the investment community as well as a number of strategic partners. Additionally, we have embarked on a formalized investor relations and corporate communications strategy to continue building off the momentum and firmly believe this will provide us with the opportunity to enhance the profile of Applied BioSciences and ultimately position us to uplist to a National Exchange. We look forward to continue providing you with updates as we execute our strategies in place.”

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development of science-driven cannabinoid therapeutics / biopharmaceuticals and delivering high-quality CBD products as well as state-of-the-art testing and analytics capabilities to our customers.

Applied BioSciences is focused on, testing and analytics, consumer and OTC brands, and partnership opportunities in the medical, health and wellness, and nutraceuticals.

The Company has several strategic partnerships currently in place and is actively pursuing additional partnerships and other strategic growth opportunities. For more information, visit the Company’s website.

Safe Harbor Statement

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Applied Biosciences Corp. (the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contact:

IR@appliedbiocorp.com
(833) 475-8247

SOURCE: Applied BioSciences Corp.

ReleaseID: 553916

LOS ANGELES, CA / ACCESSWIRE / July 30, 2019 / Lowcostcarinsuranceprice.com has launched a new blog post that explains what is the no-fault car insurance system, why it was introduced on the market and which states use it.

For more info and cheap car insurance quotes, visit https://lowcostcarinsuranceprice.com/what-is-car-insurance-no-fault-system

The no-fault system provides coverage if the policyholder or his passengers are injured during an accident. The insurer will pay for medical bills, no matter who is responsible for the accident. This type of insurance is more commonly known as personal injury protection or PIP insurance. If the policyholder is found guilty, this policy will also cover the medical costs for the other party. Besides medical bills, other costs are covered. These are presented in the blog post.

This system is not available in all states.PIP insurance is available in Florida, Hawaii, Kansas, Kentucky, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Dakota, Pennsylvania, Utah and the jurisdiction of Puerto Rico.

The system was introduced on the market with the purpose of lowering the price of auto insurance by taking the small insurance claims out of the courts. In no-fault states, drivers may sue the at-fault drivers only for severe injuries, if they meet several conditions, like exceeding a certain state threshold

For more info about this matter, check the blog post. Also, for free online quotes, please visit https://lowcostcarinsuranceprice.com/

Lowcostcarinsuranceprice.com is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

“No-fault systems will help drivers pay medical bills. Considering the astonishingly-high costs of medical care, it is recommended to purchase this coverage”, said Russell Rabichev, Marketing Director of Internet Marketing Company

CONTACT: cgurgu@internetmarketingcompany.biz

SOURCE: Internet Marketing Company

ReleaseID: 553944

HOUSTON, TX / ACCESSWIRE / July 30, 2019 / SMG Industries, Inc. (the “Company”) (OTCQB:SMGI), a growth-oriented oilfield services company operating in the Southwest United States announced today the appointment of R. Michael Villarreal to the SMG Industries, Inc. Board of Directors filling the position left by the recent passing of Director John P. Boylan.

Matthew Flemming, CEO of SMG Industries, Inc. stated “Mr. Villarreal brings many years of experience in the implementation and execution of capital raising, mergers, acquisitions and strategic partnerships with rapidly growing private and publicly-traded companies. Michael has over 14-years’ experience as an equity research analyst and investment banker covering oilfield service companies and independent producers. He has held senior level positions with Morgan Keegan, CIBC World Markets, Dillon Read & Company and Jefferies & Co. Additionally, as President of an operating business he founded ten years ago he brings experience in operational execution. He will be a great asset to the Board of Directors implementing SMGI’s buy-and-build growth strategy.” Michael received his B.B.A. in Finance from the University of Houston and is the Founder and President of Flite Banking Centers, LLC since its 2009 inception.

About SMG Industries, Inc.: SMG Industries is a rapidly growing oilfield services company that operates throughout the Southwest United States. Through its wholly-owned operating subsidiaries, the Company offers an expanding suite of products and services across the market segments of drilling, completions and production. SMG Industries, Inc. headquartered in Houston, Texas has facilities in Carthage, Odessa, Alice and Waskom, Texas. Read more at www.SMGindustries.com and www.MGCleanersllc.com and www.MomentumWTS.com.

Contact:

Matthew Flemming, SMG Industries, Inc. +1-713-821-3153

SOURCE: SMG Industries, Inc.

ReleaseID: 553938

VANCOUVER, BC / ACCESSWIRE / July 30, 2019 / Klondike Gold Corp. (TSX.V:KG)(FRA:LBDP)(OTC:KDKGF) (“Klondike Gold” or the “Company”) updates progress of the $2-million 2019 exploration program (see news May 16, 2019, and July 7, 2019) on the Company’s wholly owned 576 square kilometer Klondike District Property, Yukon Territory.

DRILLING UPDATE

A total of 42 holes have been completed testing Gay Gulch along the Eldorado Fault, plus Nugget East, Nugget, and Glacier Gulch Zones along the Nugget Fault. (This corrects previous news release which double counted drill holes). Drilling at the Lone Star Zone has commenced with an increased total of 25 holes now, for a planned total of 67 holes.

Logging, geotechnical work, sampling, and assaying are well underway. Assay results for early holes will be available shortly. Further drill assays are expected through August and September.

For location map and 2019 drill targets, refer to Figure 1: Location of 2019 Drill Target Zones and nearby prospects, Klondike District Property.

GT PROBE & SOIL SURVEY UPDATE

The Company contracted GroundTruth Exploration Inc. (“GroundTruth”) of Dawson, YT to complete its soil sampling program and its GT-Probe surveying. Gold analyses from a total of 1,671 soil samples collected covered the side slope along Eldorado Creek underlain by the Nugget Zone have been received.

The highest gold-soils correlate well with the Nugget Zone and show new high-priority prospective areas along-strike to the northwest.

A total of 100 samples contain anomalous gold soils, with gold concentrations greater than the first standard deviation (“1SD”) threshold of 29 ppb Au. A total of 37 samples have concentrations ranging from 75 ppb Au to 653 ppb Au. Refer to the Company website for analytical protocols.

The Company has received 66 rock sample assays collected from a “GT-Probe” survey also conducted by GroundTruth testing the Lone Star Zone. The GT-Probe survey tested for the continuation of Lone Star Zone gold mineralization at a 450 meter step out to the southeast. The GT Probe systematically sampled bedrock along a 325 meter line length at 5 meter intervals by collecting a rock sample from bedrock beneath the thick overburden cover using a pneumatic drill.

Results indicate a 150 meter wide anomaly of gold in bedrock between 0.15 to 0.48 g/t Au from thirteen samples. These results confirm the trend of the Lone Star Zone mineralization. Two drill holes are planned to test this wide anomaly as a priority, representing a 600 meter extension to the Lone Star Zone if successful.

LIDAR SURVEY UPDATE

McElhaney (Vancouver) completed airborne LIDAR and orthophoto surveys of the Klondike district 576 km2 property. All LIDAR data has been received, with orthophotos expected in September.

One stand-out feature identified in the imagery is clearly an old shaft, previously unknown, with a rock dump alongside in an area of the projected Nugget Zone trend where there are gold-in-soil anomalies but little bedrock information. The LIDAR imagery is under continuing review and is initially expected to help prioritize drill targets.

QUALIFIED PERSONS REVIEW

The technical and scientific information contained within this news release has been reviewed and approved by Ian Perry, P.Geol., Vice-President Exploration of Klondike Gold Corp. and Qualified Person as defined by National Instrument 43-101 policy.

ABOUT KLONDIKE GOLD CORP.

Klondike Gold Corp. is a Canadian exploration company with offices in Vancouver, British Columbia, and Dawson City, Yukon Territory. The Company is focused on exploration and development of the Lone Star gold target at the confluence of Bonanza and Eldorado Creeks, within a district scale 576 square kilometer property accessible by government maintained roads located on the outskirts of Dawson City, YT within the Tr’ondëk Hwëch’in First Nation traditional territory.

On behalf of KLONDIKE GOLD CORP.

“Peter Tallman”

President and CEO
(604) 609-6110
E-mail: info@klondikegoldcorp.com
Website: www.klondikegoldcorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

“This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. This information and statements address future activities, events, plans, developments and projections. All statements, other than statements of historical fact, constitute forward-looking statements or forward-looking information. Such forward-looking information and statements are frequently identified by words such as “may,” “will,” “should,” “anticipate,” “plan,” “expect,” “believe,” “estimate,” “intend” and similar terminology, and reflect assumptions, estimates, opinions and analysis made by management of Klondike in light of its experience, current conditions, expectations of future developments and other factors which it believes to be reasonable and relevant. Forward-looking information and statements involve known and unknown risks and uncertainties that may cause Klondike’s actual results, performance and achievements to differ materially from those expressed or implied by the forward-looking information and statements and accordingly, undue reliance should not be placed thereon.

Risks and uncertainties that may cause actual results to vary include but are not limited to the availability of financing; fluctuations in commodity prices; changes to and compliance with applicable laws and regulations, including environmental laws and obtaining requisite permits; political, economic and other risks; as well as other risks and uncertainties which are more fully described in our annual and quarterly Management’s Discussion and Analysis and in other filings made by us with Canadian securities regulatory authorities and available at www.sedar.com. Klondike disclaims any obligation to update or revise any forward-looking information or statements except as may be required.”

Figure 1: Location of 2019 Drill Target Zones and nearby prospects, Klondike District Property.

SOURCE: Klondike Gold Corp.

ReleaseID: 553923

LONDON, UK / ACCESSWIRE / July 30, 2019 / Carbios’s (Paris: ALCRB) enzyme-based technology for the decomposition of plastic polymers is well placed to exploit the trend for the minimisation of plastic waste. With a strengthened financial position post the recent rights issue and an explicit timetable for the deployment of its technology, Carbios continues its transformation from a research body into a commercial enterprise. Our DCF model indicates a valuation of €13/share.

We have revised our DCF valuation to take account of the increased number of shares in issue as a result of the rights issue (6.9m vs 4.6m) and the latest projections for the commercial deployment of Carbios’s technology (provided by Carbios at the time of the equity issue). The timetable expects commercialisation of biodegradation technology in 2020 and enzymatic recycling in 2023. The majority of projected revenue lies well into the future and remains highly uncertain, but our updated financial projections indicate a DCF-based valuation of c €13/share (€15/share before).

Click here to view the full report.

Subscribe to Edison’s content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Graeme Moyse, +44 (0)20 3077 5700
industrials@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv

SOURCE: Edison Investment Research Limited

ReleaseID: 553952